Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV/HDV co-infection in Caucasian patients

被引：0

作者：

Bazinet, Michel ^{[1
]}

Pantea, Victor ^{[2
]}

Cebotarescu, Valentin ^{[2
]}

Cojuhari, Lilia ^{[3
]}

Jimbei, Paulina ^{[3
]}

Albrecht, Jeffrey ^{[4
]}

Schmid, Peter ^{[4
]}

Karimzadeh, Hadi ^{[5
]}

Roggendorf, Michael ^{[5
]}

Vaillant, Andrew ^{[1
]}

机构：

[1] Replicor Inc, Montreal, PQ, Canada

[2] N Testemitanu State Univ Med & Pharm, Kishinev, Moldova

[3] Toma Ciorba Infect Clin Hosp, Kishinev, Moldova

[4] Natl Inst Genet, Los Angeles, CA USA

[5] Tech Univ Munich, Inst Virol, D-80290 Munich, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：222A / 222A

页数：1